CCA
MRVI icon

Canyon Capital Advisors’s Maravai LifeSciences MRVI Stock Holding History

Canyon Capital Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-600,000
Closed -$16.8M – 92
2020
Q4 		$16.8M Buy
+600,000
New +$16.7M 0.73% 25

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Canyon Capital Advisors's MRVI Position: Q1 2021 in Review

Canyon Capital Advisors sold out of Maravai LifeSciences (MRVI) in Q1 2021, closing a stake of 600,000 shares — an estimated $16.8M sold.

Canyon Capital Advisors first reported a position in MRVI in Q4 2020 and held it in 1 quarter. The position peaked at $16.8M in Q4 2020. 144 funds tracked by Wall St. Rank hold MRVI as of Q1 2021.

  • Canyon Capital Advisors reported no remaining Maravai LifeSciences position as of Q1 2021 after selling out during the quarter.
  • Canyon Capital Advisors sold 600,000 Maravai LifeSciences shares in Q1 2021, an estimated $16.8M.
  • Canyon Capital Advisors first reported a position in Maravai LifeSciences in Q4 2020 and held it in 1 quarter.
  • Canyon Capital Advisors's Maravai LifeSciences position peaked at $16.8M in Q4 2020.
  • 144 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2021.

Based on Canyon Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.